Replicel Life Sciences Inc. · OTC:REPCF
Replicel Life Sciences — Investor Presentation (May 2017)
34 slides from Replicel Life Sciences's investor presentation, May 2017
Slide 1: Company Update
1 OTCQB: REPCF TSXV: RP COMPANY UPDATE FRA:P6P2 May 2017
Slide 2: Safe Harbour Statements
Safe Harbour Statements 2 As used in this investor presentation (the “Presentation”), the terms “we”, “us”, “ours”, with the outstanding issues alleged by Shiseido in connection with the License and Co- “RepliCel” and “Company” mean ReliCel Life Sciences Inc., a British Columbia, Canada development
Slide 3: A Revolution in Sports Medicine and Aesthetics
3 A REVOLUTION IN SPORTS MEDICINE AND AESTHETICS. We are a regenerative medicine company with innovative cell therapy technology providing unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.
Slide 4: Three applications, two biologics, one game-changing delivery platform
Three applications, two biologics, one game-changing delivery platform 4 RCS-01: NBDS Fibroblast Therapy for Aging and Sun-Damaged Skin RCI-02: Dermal Injector Device RCT-01: RCH-01: NBDS Fibroblast DSC Cell Therapy Therapy for for Androgenetic Chronic Tendinosis Alopecia SPORTS MEDICINE AESTHETICS
Slide 5: How RepliCel's Innovative Cell Manufacturing Process Works
How RepliCel’s Innovative Cell Manufacturing Process Works 5 Biopsy Cells 1 Condition Diagnosed 2 taken from 3 isolated from hair scalp follicle Cells Cells injected Cells mixed 4 5 with carrier 6 into patient grow using (5-8 weeks) and frozen proprietary delivery device
Slide 6: Patented Dermal Injection Device – A Catalyst for Innovation
Patented Dermal Injection Device – A Catalyst for Innovation 6
Slide 7: Patented Dermal Injection Device – A Catalyst for Innovation
Patented Dermal Injection Device – A Catalyst for Innovation 7 The RCI-02 dermal injector Electronic injection is designed to deliver cells, activator (improves dermal fillers, drug and biologics over manual plunger) • Digital controls program for Depth, Volume, Rate of dispersion • Provides exact r
Slide 8: RepliCel is the only Company using cells derived from hair follicles
RepliCel is the only Company using cells derived from hair follicles. 8 The Hair Cycle: From growth phase to resting phase Cellular structure of a hair follicle bulb disaggregates during the regression to resting phase. GROWTH PHASE DISASSEMBLY PHASE FOLLICLE QUIESCENCE CELL REASSEMBLY GROWTH PHASE
Slide 9: Tendon Repair
9 Tendon Repair
Slide 10: The impact of losing tendon function
The mom who loves to run but has had to stop due to achilles tendinosis The worker no longer able to The impact of losing perform his job because of tendon function chronic tendon pain The passionate golfer living with golfer’s elbow who would do almost anything to enjoy a pain-free round
Slide 11: Achilles Tendon Injuries – Market Size
Achilles Tendon Injuries – Market Size 11 232,000 656,211 Estimated annual number of Achilles tendon sports injuries in Annual incidence rate the US (2002)2 of mid-portion Achilles tendinopathy in North America only1 4% of all patients seen in sports clinics have Achilles tendinosis 1 British Journa
Slide 12: Chronic Achilles Tendinosis - Predicate Science
Phase 1 Chronic Achilles Tendinosis - Predicate Science 12 63 YEAR OLD MALE Ultrasound Image Before Treatment – Day 1 Ultrasound Image After Treatment – 6 Months • 3-years of chronic pain • Pain reduction • F ailed eccentric loading, casting & • Tendon thickness reduction platelet rich plasma • Orga
Slide 13: Phase 1 Chronic Achilles Tendinosis - Predicate Science
Phase 1 Chronic Achilles Tendinosis - Predicate Science 13 PAST CLINICAL: Phase 1 Achilles Tendinosis1 Treatment with adipose-derived dermal fibroblasts 24 patients 12 treated, 12 controlled (unilateral disease) Mean age 45.2 years (20 male, 12 female) VISA questionnaire & VAS scores @ 6 months VISA
Slide 14: RCT-01 Tendon Repair
RCT-01 Tendon Repair 14 Final Results: Trial met its goal of establishing a PHASE 1/2A CLINICAL TRIAL complete safety profile at 6 months and showed no serious adverse events related to the study treatment Randomized (3:1) double-blind, or injection procedure. Most clinically material improvements s
Slide 15: One Therapy, Numerous Applications
One Therapy, Numerous Applications 15 Patellar Gluteus Medius Tennis Elbow Golfer’s Elbow Rotator Cuff Hamstring Insertion Adductor Hip Flexor
Slide 16: Dermal Rejuvenation
Se Replicel™ Using Cells for Healing
Slide 17: Impact of Aging and UV-Damaged Skin
Impact of Aging and UV-Damaged Skin 17 “It's more than vanity that drives “The impact of aging skin people's desperation to look good. may cause depression, social Your body image accounts for anxiety, lack of confidence about 1/4 to 1/3 of your and social isolation.” self-esteem, and your self-este
Slide 18: Impact of Aging and UV-Damaged Skin
Impact of Aging and UV-Damaged Skin 18 UV exposure appears to be responsible for 80% of visible facial aging signs* 35 YEARS 45 YEARS 55 YEARS 35 YEARS 45 YEARS 55 YEARS 35 YEARS 45 YEARS 55 YEARS Hyaluronic Acid 35 YEARS 45 YEARS 55 YEARS Hyaluronic Acid Collagen Elastin Collagen SKIN AGING AND COL
Slide 19: Market Size - Global Aesthetics Market
Market Size - Global Aesthetics Market 19 2013 statistics from American Society of Plastic Surgeons and GBI Research 6.7M injections up 6% YOY Botulinum Toxin 2.3M procedures up 3% YOY 6.7M Soft Tissue $2.5 Billion injections Fillers spent on facial 1.7M procedures aesthetics in 2013 up 18% YOY Hyal
Slide 20: RCS - Dermal Rejuvenation
RCS - 01 Dermal Rejuvenation 20 PHASE 1 CLINICAL TRIAL Interim Results: No serious adverse events at the interim point of the trial were reported. With respect to efficacy, the nearly two-fold increase Phase 1 randomized, in gene expression of collagen-related biomarkers in the skin, after a single
Slide 21: Pattern Baldness
# @ Replicel” Using Cells for Healing
Slide 22: Impact of Hair Loss
Impact of Hair Loss 22 “I’m a 42 year-old woman suffering from alopecia. I cry myself to sleep at least once a week.” “I’m a 24-year old who feels the impact of my baldness on my career and social life on a daily basis.” 1 Androgenetic Alopecia There is currently only one affects an estimated FDA-ap
Slide 23: Market Size - Hair Loss Treatments
Market Size - Hair Loss Treatments 23 2015 Practice Census Results – International Society of Hair Restoration Surgery 358,109 surgical patients All figures in USD 697,372 non-surgical patients Hair restoration Patients $3.5 Billion spent on all $2.5B spent on surgical procedures hair loss treatment
Slide 24: RCH-01 Pattern Baldness
RCH-01 Pattern Baldness 24 PHASE 2 CLINICAL STUDY PHASE 1 STUDY RESULTS: Study results from first-in-human, five-year clinical trial Japan Potential Market Launch. Costs firmly establishes product safety. Efficacy data collected (ongoing) covered by Shiseido, Data expected 2018. Potential near- from
Slide 25: RCH-01 Pattern Baldness (Continued) – ROW Licensing
RCH-01 Pattern Baldness (Continued) 25 ROW LICENSING Strong ongoing interest by several parties including multinational companies in the aesthetic industry, including Shiseido (Japan) • Geographic license for pattern baldness only for Japan, China, Korea and ASEAN nations • $35 Million ($4M upfront,
Slide 26: In transition from early-stage pre-revenue company to near-term revenue generator
In transition from early-stage pre-revenue company 26 to near-term revenue generator 2017 2018 Q1: Q2 2018: • Interim analysis of 6-month post-injection safety • Expected Data Readout from clinical study and efficacy data from the Phase 1/2 trial of RCT-01 of RCH-01 – Japan • Interim analysis of 6-m
Slide 27: Strong Near-Term Clinical Pipeline
Strong Near-Term Clinical Pipeline 27 Indication Product Phase Data Location Chronic Tendinosis RCT-01 1/2 2017 Q1 Canada Aging and RCS-01 1 2017 Q1 Germany Sun-damaged Skin Pattern Baldness RCH-01 1 2017 Q1 Georgia Pattern Baldness RCH-01 2 2018 Japan* *Funded by Shiseido – See RepliCel’s news rele
Slide 28: Actively engaged in licensing and co-development deals over the next 24 months
Actively engaged in licensing and co-development deals 28 over the next 24 months Company is structured to minimize its own infrastructure and leverage partners for commercialization. Maximum shareholder With a multinational partnership already in value creation is in place with Shiseido*, RepliCel
Slide 29: Capital Structure
Capital Structure 29 OTCQB: REPCF TSXV: RP FRA:P6P2 Current market cap. (approx.) ~$25M Total money raised through equity to-date ~$25M Total revenue to-date $3.8M (initial Shiseido licensing payment) Current Monthly Burn Rate ~$180,000 Shares Outstanding (Basic/FD) 18.3M common shares issued and ou
Slide 30: Board & Management
Board & Management 30 David Hall Mr. Hall served as CEO and President of RepliCel Life Sciences from 2012 through 2015. Previously, Mr. Hall consulted to government, pharma industry, biotech, eHealth and NGO’s for two years. For the prior 15 years, Mr. Hall was a Chairman business founder, CFO, CCO,
Slide 31: Board & Management (cont'd)
Board & Management (cont’d) 31 R. Lee Buckler, B. Ed, LLB Former Managing Director of Cell Therapy Group, Mr. Buckler served six years as the Executive Director of the International Society for Cellular Therapy and just over two years as Director of Business Development for President, CEO & Director
Slide 32: Clinical Advisory Board – RCT-01
Clinical Advisory Board – RCT-01 32 Dr. Ross G. Davidson, Dr. Davidson is the past president of the National Hockey League Physicians Society, past head physician and orthopaedic consultant for the Vancouver Canucks Hockey Club (NHL), past orthopaedic consultant to the MBChB. FRCS (C). DABOS, Vancou
Slide 33: 2017 – Poised for growth and momentum
2017 – Poised for growth and momentum 33 THE ONLY REGENERATIVE POTENTIAL TO MULTIPLE ASSETS NEAR-TERM MEDICINE COMPANY REVOLUTIONIZE ADDRESSING CONDITIONS COMMERCIALIZATION USING HAIR FOLLICLE SPORTS MEDICINE WITH SIGNIFICANT AND REVENUE CELL THERAPY AND AESTHETICS UNMET NEED We are the only Company
Slide 34: Contact
34 CONTACT R. Lee Buckler President & CEO 604.248.8693 lee@replicel.com OTCQB: REPCF TSXV: RP FRA:P6P2 VISIT US ON SOCIAL MEDIA
RepliCel Life Sciences — Investor Presentation (May 2017) on 6ix